Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)

9 Months Ended

Sep. 30, 2023

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended September 30, 2023		Diagnostics				Therapeutics				Corporate				Total
Research and development expenses		$	745,758			$	83,855			$	—			$	829,613
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				1,772				1,272,926				1,274,698
Depreciation and amortization ⁽²⁾			9,526				—				17,501				27,027
Loss from operations ⁽³⁾			(755,284	)			(85,627	)			(1,290,427	)			(2,131,338	)
Other expense, net ⁽⁴⁾			—				—				(124,001	)			(124,001	)
Loss from continuing operations			(755,284	)			(85,627	)			(1,414,428	)			(2,255,339	)
Total assets, net of depreciation and amortization:
United States		$	—			$	—			$	5,130,396			$	5,130,396
International			559,455				—				12,568				572,023

Three Months Ended September 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
International		$	7,516			$	—			$	—			$	7,516
Grant and other revenue			—				—				—				—
Total revenue			7,516				—				—				7,516
Cost of revenue, excluding depreciation and amortization			1,432				—				—				1,432
Reserve for expiring inventory			133,006				—				—				133,006
Research and development expenses			1,073,950				112,469				—				1,186,419
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				745				3,612,002				3,612,747
Depreciation and amortization ⁽²⁾			8,532				—				16,171				24,703
Loss from operations ⁽³⁾			(1,209,404	)			(113,214	)			(3,628,173	)			(4,950,791	)
Other expense, net ⁽⁴⁾			—				—				(757,034	)			(757,034	)
Net loss			(1,209,404	)			(113,214	)			(4,385,207	)			(5,707,825	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	5,929,692			$	5,979,692
International			271,939				—				6,801				278,740
Capital expenditures			14,429				—				—				14,429

Nine Months Ended September 30, 2023		Diagnostics				Therapeutics				Corporate				Total
Research and development expenses		$	2,973,357			$	229,974			$	—			$	3,203,331
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				4,832				3,691,525				3,696,357
Depreciation and amortization ⁽²⁾			28,328				—				53,389				81,717
Loss from operations ⁽³⁾			(3,001,685	)			(234,806	)			(3,744,914	)			(6,981,405	)
Other income, net ⁽⁴⁾			—				—				1,856,552				1,856,552
Loss from continuing operations			(3,001,685	)			(234,806	)			(1,888,362	)			(5,124,853	)
Total assets, net of depreciation and amortization:
United States		$	—			$	—			$	5,130,396			$	5,130,396
International			559,455				—				12,568				572,023
Capital expenditures			15,068				—				—				15,068

Nine Months Ended September 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
International		$	14,035			$	—			$	—			$	14,035
Grant and other revenue			51,007				—				—				51,007
Total revenue			65,042				—				—				65,042
Cost of revenue, excluding depreciation and amortization			1,905				—				—				1,905
Reserve for expiring inventory			133,006				—				—				133,006
Research and development expenses			3,700,528				379,133				—				4,079,661
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,746				6,630,047				6,633,793
Depreciation and amortization ⁽²⁾			20,613				—				48,739				69,352
Loss from operations ⁽³⁾			(3,791,010	)			(382,879	)			(6,678,786	)			(10,852,675	)
Other expense, net ⁽⁴⁾			—				—				(841,853	)			(841,853	)
Net loss			(3,791,010	)			(382,879	)			(7,520,639	)			(11,694,528	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	5,929,692			$	5,979,692
International			271,939				—				6,801				278,740
Capital expenditures			54,650				—				8,436				63,086